Incidence of bacteremias and invasive mycoses in children with high risk neuroblastoma

Elio Castagnola, Massimo Conte, Stefano Parodi, Filippo Papio, Ilaria Caviglia, Riccardo Haupt

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. Information on the incidence of infectious complications during for treatment for high risk neuroblastoma (HR-NB) is limited. Bacteremias and invasive mycoses may be considered surrogate markers of the infection burden. Patients and Methods. Data on bacteremias and invasive mycoses occurring during 3 consecutive protocols for front line (NB-89; NB-92; NB-97) or salvage therapy (TVD) for HR-NB were reviewed. The cumulative risk of developing a first episode and the rate of infections during the entire length of each protocol were evaluated. Results. Front line protocols were given to 80 patients for a total of 22,070 days at risk; salvage treatment was given to 24 children for 2,909 days at risk. During front line therapy 41 infectious episodes were diagnosed in 29 (36%) patients, for a 45% cumulative risk and an infection rate (IR) of 0.19/100 patient-days-at risk. Salvage therapy determined five infectious episodes in four (17%) patients, with a 39% cumulative risk, and an IR of 0.17. The IR during the phase of high dose chemotherapy with hematopoietic stem cell rescue (megatherapy) included in the three front line protocols decreased over time (1.54 in NB-89; 0.52 in NB-92 and 0.0 in NB 97; P = 0.001), possibly because of the use of less aggressive conditioning regimens, without radiotherapy. Conclusions. The IRs of protocols for HR-NB did not change over time. The megatherapy-related phases are those at highest risk.

Original languageEnglish
Pages (from-to)672-677
Number of pages6
JournalPediatric Blood and Cancer
Volume49
Issue number5
DOIs
Publication statusPublished - Oct 15 2007

Fingerprint

Bacteremia
Neuroblastoma
Incidence
Salvage Therapy
Infection
Invasive Fungal Infections
Hematopoietic Stem Cells
Radiotherapy
Biomarkers
Drug Therapy
Therapeutics

Keywords

  • Incidence
  • Infectious complications
  • Neuroblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Incidence of bacteremias and invasive mycoses in children with high risk neuroblastoma. / Castagnola, Elio; Conte, Massimo; Parodi, Stefano; Papio, Filippo; Caviglia, Ilaria; Haupt, Riccardo.

In: Pediatric Blood and Cancer, Vol. 49, No. 5, 15.10.2007, p. 672-677.

Research output: Contribution to journalArticle

@article{a87aa64f42d3456a8a6cfb5d89865270,
title = "Incidence of bacteremias and invasive mycoses in children with high risk neuroblastoma",
abstract = "Background. Information on the incidence of infectious complications during for treatment for high risk neuroblastoma (HR-NB) is limited. Bacteremias and invasive mycoses may be considered surrogate markers of the infection burden. Patients and Methods. Data on bacteremias and invasive mycoses occurring during 3 consecutive protocols for front line (NB-89; NB-92; NB-97) or salvage therapy (TVD) for HR-NB were reviewed. The cumulative risk of developing a first episode and the rate of infections during the entire length of each protocol were evaluated. Results. Front line protocols were given to 80 patients for a total of 22,070 days at risk; salvage treatment was given to 24 children for 2,909 days at risk. During front line therapy 41 infectious episodes were diagnosed in 29 (36{\%}) patients, for a 45{\%} cumulative risk and an infection rate (IR) of 0.19/100 patient-days-at risk. Salvage therapy determined five infectious episodes in four (17{\%}) patients, with a 39{\%} cumulative risk, and an IR of 0.17. The IR during the phase of high dose chemotherapy with hematopoietic stem cell rescue (megatherapy) included in the three front line protocols decreased over time (1.54 in NB-89; 0.52 in NB-92 and 0.0 in NB 97; P = 0.001), possibly because of the use of less aggressive conditioning regimens, without radiotherapy. Conclusions. The IRs of protocols for HR-NB did not change over time. The megatherapy-related phases are those at highest risk.",
keywords = "Incidence, Infectious complications, Neuroblastoma",
author = "Elio Castagnola and Massimo Conte and Stefano Parodi and Filippo Papio and Ilaria Caviglia and Riccardo Haupt",
year = "2007",
month = "10",
day = "15",
doi = "10.1002/pbc.21070",
language = "English",
volume = "49",
pages = "672--677",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Incidence of bacteremias and invasive mycoses in children with high risk neuroblastoma

AU - Castagnola, Elio

AU - Conte, Massimo

AU - Parodi, Stefano

AU - Papio, Filippo

AU - Caviglia, Ilaria

AU - Haupt, Riccardo

PY - 2007/10/15

Y1 - 2007/10/15

N2 - Background. Information on the incidence of infectious complications during for treatment for high risk neuroblastoma (HR-NB) is limited. Bacteremias and invasive mycoses may be considered surrogate markers of the infection burden. Patients and Methods. Data on bacteremias and invasive mycoses occurring during 3 consecutive protocols for front line (NB-89; NB-92; NB-97) or salvage therapy (TVD) for HR-NB were reviewed. The cumulative risk of developing a first episode and the rate of infections during the entire length of each protocol were evaluated. Results. Front line protocols were given to 80 patients for a total of 22,070 days at risk; salvage treatment was given to 24 children for 2,909 days at risk. During front line therapy 41 infectious episodes were diagnosed in 29 (36%) patients, for a 45% cumulative risk and an infection rate (IR) of 0.19/100 patient-days-at risk. Salvage therapy determined five infectious episodes in four (17%) patients, with a 39% cumulative risk, and an IR of 0.17. The IR during the phase of high dose chemotherapy with hematopoietic stem cell rescue (megatherapy) included in the three front line protocols decreased over time (1.54 in NB-89; 0.52 in NB-92 and 0.0 in NB 97; P = 0.001), possibly because of the use of less aggressive conditioning regimens, without radiotherapy. Conclusions. The IRs of protocols for HR-NB did not change over time. The megatherapy-related phases are those at highest risk.

AB - Background. Information on the incidence of infectious complications during for treatment for high risk neuroblastoma (HR-NB) is limited. Bacteremias and invasive mycoses may be considered surrogate markers of the infection burden. Patients and Methods. Data on bacteremias and invasive mycoses occurring during 3 consecutive protocols for front line (NB-89; NB-92; NB-97) or salvage therapy (TVD) for HR-NB were reviewed. The cumulative risk of developing a first episode and the rate of infections during the entire length of each protocol were evaluated. Results. Front line protocols were given to 80 patients for a total of 22,070 days at risk; salvage treatment was given to 24 children for 2,909 days at risk. During front line therapy 41 infectious episodes were diagnosed in 29 (36%) patients, for a 45% cumulative risk and an infection rate (IR) of 0.19/100 patient-days-at risk. Salvage therapy determined five infectious episodes in four (17%) patients, with a 39% cumulative risk, and an IR of 0.17. The IR during the phase of high dose chemotherapy with hematopoietic stem cell rescue (megatherapy) included in the three front line protocols decreased over time (1.54 in NB-89; 0.52 in NB-92 and 0.0 in NB 97; P = 0.001), possibly because of the use of less aggressive conditioning regimens, without radiotherapy. Conclusions. The IRs of protocols for HR-NB did not change over time. The megatherapy-related phases are those at highest risk.

KW - Incidence

KW - Infectious complications

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=35148880648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148880648&partnerID=8YFLogxK

U2 - 10.1002/pbc.21070

DO - 10.1002/pbc.21070

M3 - Article

C2 - 17039488

AN - SCOPUS:35148880648

VL - 49

SP - 672

EP - 677

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -